Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular assessment of ponatinib in chronic phase CML after imatinib and bosutinib failure (CarPAs)
2018-001334-18Phase 2Terminated
- Sponsor
- Associazione Italiana Pazienti Leucemia Mieloide Cronica
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by Associazione Italiana Pazienti Leucemia Mieloide Cronica. Primary endpoint: Exposure adjusted rate of arterial occlusive events (AOE) and serious arterial occlusive events (SOE) at 1 year. Started Oct 2020; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-001334-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001334-18.